4.82 USD
-0.12 (-2.43%)
We assign a fundamental rating of 4 out of 10 to NTRB. NTRB was compared to 192 industry peers in the Pharmaceuticals industry. NTRB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. NTRB is not overvalued while it is showing excellent growth. This is an interesting combination.
1. Profitability
1.1 Basic Checks
In the past year NTRB has reported negative net income.
NTRB had a negative operating cash flow in the past year.
NTRB had negative earnings in each of the past 5 years.
NTRB had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of NTRB (-315.26%) is worse than 93.75% of its industry peers.
The Return On Equity of NTRB (-377.72%) is worse than 77.60% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -315.26% | ||
| ROE | -377.72% | ||
| ROIC | N/A |
ROA(3y)-86.9%
ROA(5y)-68.06%
ROE(3y)-100.18%
ROE(5y)-79.11%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NTRB's Gross Margin of 34.36% is in line compared to the rest of the industry. NTRB outperforms 57.81% of its industry peers.
In the last couple of years the Gross Margin of NTRB has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for NTRB so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 34.36% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.68%
GM growth 5YN/A
2. Health
2.1 Basic Checks
NTRB does not have a ROIC to compare to the WACC, probably because it is not profitable.
NTRB has more shares outstanding than it did 1 year ago.
The number of shares outstanding for NTRB has been increased compared to 5 years ago.
The debt/assets ratio for NTRB has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 14.18 indicates that NTRB is not in any danger for bankruptcy at the moment.
The Altman-Z score of NTRB (14.18) is better than 85.42% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that NTRB is not too dependend on debt financing.
With a decent Debt to Equity ratio value of 0.01, NTRB is doing good in the industry, outperforming 60.42% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 14.18 |
ROIC/WACCN/A
WACC8.98%
2.3 Liquidity
NTRB has a Current Ratio of 4.78. This indicates that NTRB is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 4.78, NTRB is doing good in the industry, outperforming 63.54% of the companies in the same industry.
NTRB has a Quick Ratio of 4.70. This indicates that NTRB is financially healthy and has no problem in meeting its short term obligations.
NTRB has a Quick ratio of 4.70. This is in the better half of the industry: NTRB outperforms 65.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.78 | ||
| Quick Ratio | 4.7 |
3. Growth
3.1 Past
NTRB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -255.00%.
NTRB shows a strong growth in Revenue. In the last year, the Revenue has grown by 42.93%.
NTRB shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 41.99% yearly.
EPS 1Y (TTM)-255%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1276.65%
Revenue 1Y (TTM)42.93%
Revenue growth 3Y14.58%
Revenue growth 5Y41.99%
Sales Q2Q%40.47%
3.2 Future
The Earnings Per Share is expected to grow by 100.83% on average over the next years. This is a very strong growth
NTRB is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 334.01% yearly.
EPS Next Y6.67%
EPS Next 2Y110.16%
EPS Next 3Y100.83%
EPS Next 5YN/A
Revenue Next Year528.03%
Revenue Next 2Y557.52%
Revenue Next 3Y334.01%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for NTRB. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 3.26, the valuation of NTRB can be described as very cheap.
Compared to the rest of the industry, the Price/Forward Earnings ratio of NTRB indicates a rather cheap valuation: NTRB is cheaper than 98.96% of the companies listed in the same industry.
NTRB is valuated cheaply when we compare the Price/Forward Earnings ratio to 36.21, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 3.26 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
NTRB's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
NTRB's earnings are expected to grow with 100.83% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y110.16%
EPS Next 3Y100.83%
5. Dividend
5.1 Amount
No dividends for NTRB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:NTRB (12/2/2025, 1:18:28 PM)
4.82
-0.12 (-2.43%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners2.89%
Inst Owner Change7.47%
Ins Owners55.75%
Ins Owner Change0%
Market Cap57.98M
Revenue(TTM)2.58M
Net Income(TTM)-32.08M
Analysts82.86
Price Target15.3 (217.43%)
Short Float %4.6%
Short Ratio4.94
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)11.33%
Min EPS beat(2)-3.81%
Max EPS beat(2)26.47%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-7.55%
Min Revenue beat(2)-13.5%
Max Revenue beat(2)-1.6%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-1021.05%
EPS NQ rev (3m)-1021.05%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-6.9%
Revenue NQ rev (3m)-6.9%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 3.26 | ||
| P/S | 22.49 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 6.83 | ||
| P/tB | 8.86 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.87
EYN/A
EPS(NY)1.48
Fwd EY30.68%
FCF(TTM)-0.41
FCFYN/A
OCF(TTM)-0.41
OCFYN/A
SpS0.21
BVpS0.71
TBVpS0.54
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -315.26% | ||
| ROE | -377.72% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 34.36% | ||
| FCFM | N/A |
ROA(3y)-86.9%
ROA(5y)-68.06%
ROE(3y)-100.18%
ROE(5y)-79.11%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.68%
GM growth 5YN/A
F-Score4
Asset Turnover0.25
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 20.01% | ||
| Cap/Sales | 2.02% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.78 | ||
| Quick Ratio | 4.7 | ||
| Altman-Z | 14.18 |
F-Score4
WACC8.98%
ROIC/WACCN/A
Cap/Depr(3y)24.77%
Cap/Depr(5y)N/A
Cap/Sales(3y)3.53%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-255%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1276.65%
EPS Next Y6.67%
EPS Next 2Y110.16%
EPS Next 3Y100.83%
EPS Next 5YN/A
Revenue 1Y (TTM)42.93%
Revenue growth 3Y14.58%
Revenue growth 5Y41.99%
Sales Q2Q%40.47%
Revenue Next Year528.03%
Revenue Next 2Y557.52%
Revenue Next 3Y334.01%
Revenue Next 5YN/A
EBIT growth 1Y-7.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-60.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-59.09%
OCF growth 3YN/A
OCF growth 5YN/A
NUTRIBAND INC / NTRB FAQ
Can you provide the ChartMill fundamental rating for NUTRIBAND INC?
ChartMill assigns a fundamental rating of 4 / 10 to NTRB.
What is the valuation status of NUTRIBAND INC (NTRB) stock?
ChartMill assigns a valuation rating of 4 / 10 to NUTRIBAND INC (NTRB). This can be considered as Fairly Valued.
Can you provide the profitability details for NUTRIBAND INC?
NUTRIBAND INC (NTRB) has a profitability rating of 1 / 10.
How financially healthy is NUTRIBAND INC?
The financial health rating of NUTRIBAND INC (NTRB) is 6 / 10.
What is the expected EPS growth for NUTRIBAND INC (NTRB) stock?
The Earnings per Share (EPS) of NUTRIBAND INC (NTRB) is expected to grow by 6.67% in the next year.